CUE VS AADI Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility

Performance

CUE
10/100

CUE returned -33.33% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

AADI
10/100

AADI returned -64.24% in the last 12 months. Based on SPY's performance of -13.86%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

CUE
75/100

1 analysts offer 12-month price targets for CUE. Together, they have an average target of 7, the most optimistic target put CUE at 7 within 12-months and the most pessimistic has CUE at 7.

AADI

"Analyst Price Targets" not found for AADI

Sentiment

CUE
74/100

CUE had a bullish sentiment score of 74.32% across Twitter and StockTwits over the last 12 months. It had an average of 2.59 posts, 1.65 comments, and 3.88 likes per day.

AADI

"Sentiment" not found for AADI

Technicals

CUE
64/100

CUE receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

AADI
57/100

AADI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

Earnings

CUE
10/100

CUE has missed earnings 6 times in the last 20 quarters.

AADI
10/100

AADI has missed earnings 9 times in the last 20 quarters.

Profit

CUE
10/100

Out of the last 20 quarters, CUE has had 0 profitable quarters and has increased their profits year over year on 0 of them.

AADI
13/100

Out of the last 20 quarters, AADI has had 2 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

CUE
40/100

CUE has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

AADI
39/100

AADI has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Cue Biopharma, Inc. Summary

Nasdaq / CUE
Healthcare
Biotechnology
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Aadi Bioscience, Inc. Common Stock Summary

Nasdaq / AADI
Healthcare
Biotechnology
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.